Overview

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes

Status:
Active, not recruiting
Trial end date:
2021-12-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 1 diabetes (T1D).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin Glargine
Insulin Lispro
Insulin, Globin Zinc
Insulin, Long-Acting